Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:NXL NASDAQ:OSRH NASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.20+3.4%$2.61$1.98▼$22.25$16.50M-0.4663,579 shs46,265 shsNXLNexalin Technology$0.84-1.6%$0.96$0.59▼$4.49$14.81M3.682.85 million shs149,049 shsOSRHOSR$0.58-3.0%$0.88$0.45▼$13.40$12.80M1.5113.91 million shs183,963 shsQNRXQuoin Pharmaceuticals$7.52-1.3%$7.94$5.01▼$54.95$4.48M1.592,549 shs1,498 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies+3.43%+1.99%-22.16%-18.41%-85.86%NXLNexalin Technology-1.64%-12.57%-15.55%-35.19%-9.32%OSRHOSR-3.00%-25.95%-13.01%-57.72%+57,499,900.00%QNRXQuoin Pharmaceuticals-1.31%-1.97%+3.78%-14.74%-72.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.20+3.4%$2.61$1.98▼$22.25$16.50M-0.4663,579 shs46,265 shsNXLNexalin Technology$0.84-1.6%$0.96$0.59▼$4.49$14.81M3.682.85 million shs149,049 shsOSRHOSR$0.58-3.0%$0.88$0.45▼$13.40$12.80M1.5113.91 million shs183,963 shsQNRXQuoin Pharmaceuticals$7.52-1.3%$7.94$5.01▼$54.95$4.48M1.592,549 shs1,498 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies+3.43%+1.99%-22.16%-18.41%-85.86%NXLNexalin Technology-1.64%-12.57%-15.55%-35.19%-9.32%OSRHOSR-3.00%-25.95%-13.01%-57.72%+57,499,900.00%QNRXQuoin Pharmaceuticals-1.31%-1.97%+3.78%-14.74%-72.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 2.50Moderate Buy$22.83936.47% UpsideNXLNexalin Technology 3.00Buy$5.00498.01% UpsideOSRHOSR 0.00N/AN/AN/AQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNRX, NXL, ALUR, and OSRH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025ALURAllurion TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$32.11M0.53N/AN/A($30.08) per share-0.07NXLNexalin Technology$170K85.68N/AN/A$0.28 per share2.99OSRHOSRN/AN/AN/AN/A($3.87) per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$35.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$7.20M-$12.53N/AN/AN/A-158.30%N/A-59.91%11/12/2025 (Estimated)NXLNexalin Technology-$7.61M-$0.76N/A∞N/A-5,057.14%-209.20%-186.87%N/AOSRHOSR-$2.41MN/A0.00∞N/AN/A-12.19%-8.18%N/AQNRXQuoin Pharmaceuticals-$8.96M-$41.45N/AN/AN/AN/A-210.50%-99.41%11/6/2025 (Estimated)Latest QNRX, NXL, ALUR, and OSRH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025ALURAllurion Technologies-$0.65-$0.57+$0.08-$1.28$6.20 million$3.38 million8/14/2025Q2 2025OSRHOSRN/A$0.02N/A$0.02N/A$1.14 million8/7/2025Q2 2025QNRXQuoin Pharmaceuticals-$6.83-$6.28+$0.55-$6.28N/AN/A8/6/2025Q2 2025NXLNexalin Technology-$0.14-$0.10+$0.04-$0.10$0.04 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.021.70NXLNexalin TechnologyN/A10.4310.14OSRHOSRN/A0.180.17QNRXQuoin PharmaceuticalsN/A1.961.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%NXLNexalin Technology0.65%OSRHOSR55.30%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%NXLNexalin Technology25.26%OSRHOSR33.67%QNRXQuoin Pharmaceuticals13.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.76 million6.02 millionOptionableNXLNexalin Technology317.42 million13.02 millionNot OptionableOSRHOSRN/A21.58 million14.32 millionN/AQNRXQuoin Pharmaceuticals4590,000509,000Not OptionableQNRX, NXL, ALUR, and OSRH HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate UpdateSeptember 3 at 12:31 PM | theglobeandmail.comQuoin Pharmaceuticals Announces CFO Departure AgreementAugust 27, 2025 | msn.comQuoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton SyndromeAugust 21, 2025 | markets.businessinsider.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyAugust 18, 2025 | finanznachrichten.deQuoin Pharmaceuticals appoints Lawlor as Chief Financial OfficerAugust 18, 2025 | msn.comQuoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyAugust 18, 2025 | globenewswire.comQuoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-EastonAugust 12, 2025 | globenewswire.comQNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate TimelineAugust 8, 2025 | finance.yahoo.comQuoin (QNRX) Q2 Loss Beats EstimatesAugust 7, 2025 | fool.comQuoin Pharmaceuticals stock rises after positive clinical updatesJuly 31, 2025 | investing.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | finanznachrichten.deQuoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | globenewswire.comQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - MorningstarJune 27, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - NasdaqJune 27, 2025 | nasdaq.comQNRX - Quoin Pharmaceuticals Ltd ADR Executives - MorningstarJune 26, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin DiseasesJune 26, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton SyndromeJune 24, 2025 | tmcnet.comQuoin Pharmaceuticals, Ltd. (QNRX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comQNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand FurtherMay 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNRX, NXL, ALUR, and OSRH Company DescriptionsAllurion Technologies NYSE:ALUR$2.20 +0.07 (+3.43%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$2.15 -0.05 (-2.18%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Nexalin Technology NASDAQ:NXL$0.84 -0.01 (-1.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.84 +0.00 (+0.35%) As of 09/5/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.OSR NASDAQ:OSRH$0.57 -0.02 (-3.00%) As of 09/5/2025 03:59 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Quoin Pharmaceuticals NASDAQ:QNRX$7.52 -0.10 (-1.31%) Closing price 09/5/2025 03:58 PM EasternExtended Trading$7.18 -0.34 (-4.51%) As of 09/5/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
